Gregory Ferenstein
Gregory Ferenstein is a senior fellow in drug policy at Reason Foundation.
-
FAQ: Timeline for FDA ibogaine approval
It can take between 5 and 12 years to complete a drug trial, but the timeline to drug approval can vary significantly depending on the type of treatment.
-
New York’s stalled AI bill would have blurred the line between disclosure and restriction
While pitched as a transparency measure, Assembly Bill 8595 would have set a new, unusually high bar for compliance.
-
Democrats pivot on AI: Less regulation, more redistribution
The focus of Sen. Mark Kelly’s “AI for America” plan departs from other federal artificial intelligence policy proposals introduced by Democrats.
-
Sen. Ted Cruz proposes federal regulatory sandbox to encourage AI innovation, development
The SANDBOX Act would allow innovators to obtain temporary regulatory waivers for artificial intelligence technologies from federal agencies.
-
A look at the White House’s pro-innovation artificial intelligence ‘action plan’
The White House's AI action plan represents a clear policy direction favoring rapid innovation and reduced regulatory oversight.
-
Psychedelics Policy Newsletter: DEA considers rescheduling psilocybin, FDA releases rejection decision, and more
Plus: Reason Foundation testifies in Mississippi, author Joe Dolce talks about his new psychedelics book, and more.
-
State psychedelics legalization and policy roundup — October 2025
Kentucky debates clinical ibogaine trials, Mississippi considers ibogaine, Massachusetts bill would decriminalize psilocybin, and more.
-
Colorado can lead on AI fairness without a regulatory straitjacket
There are evidence-based, market-oriented steps Colorado lawmakers could take in place of the state's existing artificial intelligence law.
-
Next steps after the Senate rejected an AI regulation moratorium
The Senate's compromise effort for a federal moratorium on state laws regulating AI may show the way toward a politically viable path.
-
Psychedelics Policy Newsletter: RFK Jr. gives hopeful approval timeline, Arizona advances ibogaine, and more
Plus: Former Texas Gov. Rick Perry on his strong commitment to advancing ibogaine as a treatment.
-
State psychedelics legalization and policy roundup — August 2025
Arizona allocates funding for ibogaine research, Reason Foundation to testify at Mississippi informational hearing about ibogaine, and more.
-
Existing laws already fight AI housing discrimination—new state AI bills increase confusion
Misguided artificial intelligence regulatory efforts risk limiting innovation and sowing misunderstanding in many markets.
-
Vermont attempts to regulate political AI deepfakes
Vermont lawmakers have introduced Senate Bill S.23, a proposal aimed at curbing the use of AI-generated synthetic media in state elections.
-
New York’s RAISE Act expands executive power over AI at the expense of legislative oversight
New York is the latest in a growing number of states attempting to regulate artificial intelligence.
-
Congress, states explore AI tools to fight Medicare, Medicaid fraud
Continued investment in artificial intelligence may help agencies achieve more accurate oversight and reduce waste in public health care spending.
-
Psychedelics Policy Newsletter: FDA prioritizes drug reform for psychedelics, Texas advances ibogaine research, and more
Plus: New psychedelics-related hire at the Department of Health and Human Services, update on state progress, and more.
-
State psychedelics legalization and policy roundup — June 2025
While many good psychedelics reforms failed to pass, there were a few notable wins from 2025 state legislative sessions.
-
California’s Senate Bill 813 is a novel approach to AI safety
The bill’s approach may serve as a viable alternative to heavy-handed regulation, but lawmakers should proceed carefully.
